The life of Cipla, the Indian pharma giant, can broadly be divided into three parts: the first 8 decades of altruistic ...

Nomura has a Buy rating on Cipla after the company's MD reassured that the competitiveness of the Indian generics biz won't ...

Welcome to the Cipla Stock Liveblog, your ultimate source for real-time updates and analysis of one of the most prominent ...

A global collaboration towards a secure supply-chain or a differentiated manufacturing model are just some of the options ...

Indian pharmaceutical industry leaders indicate that proposed US tariffs on pharmaceutical exports may lead to increased drug ...

India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...

Good afternoon and welcome to the MannKind Corporation Fourth Quarter and Year End 2024 Financial Results Earnings Call. As a reminder, this call is being recorded on February 26, 2025 and will be ...

Pulmonary Or Respiratory Drug Delivery Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 The Business Research ...

Mumbai: Pharma major, Sun Pharmaceutical, is gearing up to introduce its experimental anti-obesity and type 2 diabetes ...

If successful, Mankind’s drug would be the first oral small-molecule alternative, offering a pill-based treatment.